https://specialty.mims.com/topic/novel-bispecific-antibody-exudes-promise-for-relapsed-refractory-dlbcl
In a phase I/II study, the novel T-cell-engaging bispecific antibody glofitamab bares its potential for relapsed or refractory diffuse large B-cell ly...
Create an account or login to join the discussion